Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc. (BJDX): 1 pipeline candidate · ~7 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.1 months
D/E 0.34 · 0% dilution
Lead: Preclinical
1 candidate
N/A
5 buys · 0 sells (180d)
A transparent, data-derived signal for Bluejay Diagnostics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.7M
Cash
$3.7M
Quarterly Burn
$1.6M
Runway
7.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| allereye | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 28,726 | $53K |
| geode capital management, llc | 28,127 | $52K |
Frequently asked questions
How many drug candidates are in Bluejay Diagnostics Inc.'s pipeline?
Bluejay Diagnostics Inc. (BJDX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bluejay Diagnostics Inc.'s lead drug candidate?
Bluejay Diagnostics Inc.'s most advanced tracked candidate is allereye (Preclinical) for Allergic Conjunctivitis.
What is Bluejay Diagnostics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bluejay Diagnostics Inc. has approximately 7.1 months of cash runway.
What is Bluejay Diagnostics Inc.'s market capitalization?
Bluejay Diagnostics Inc.'s market capitalization is approximately $4.7M.
Who is the CEO of Bluejay Diagnostics Inc.?
Mr. Indranil Dey is the chief executive officer of Bluejay Diagnostics Inc. (BJDX).
Get the full picture on Bluejay Diagnostics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.